Cardiff Oncology マネジメント
マネジメント 基準チェック /34
Cardiff Oncology's CEO is Mark Erlander, appointed in May 2020, has a tenure of 4.5 years. total yearly compensation is $1.55M, comprised of 38.4% salary and 61.6% bonuses, including company stock and options. directly owns 0.053% of the company’s shares, worth $78.46K. The average tenure of the management team and the board of directors is 2.8 years and 10.2 years respectively.
主要情報
Mark Erlander
最高経営責任者
US$1.5m
報酬総額
| CEO給与比率 | 38.4% |
| CEO在任期間 | 4.5yrs |
| CEOの所有権 | 0.05% |
| 経営陣の平均在職期間 | 2.8yrs |
| 取締役会の平均在任期間 | 10.2yrs |
経営陣の近況
Recent updates
We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Oct 09
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
Oct 04We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely
Jun 19Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Mar 09We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Mar 03Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Nov 16Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 01Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Feb 22Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Sep 14Cardiff Oncology: Down But Not Out
Aug 22Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Jun 20Cardiff Oncology: Upcoming Readouts And Several Green Lights
Jun 07Cardiff Oncology: Risky Investment
May 19Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
Mar 01We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Jan 28Cardiff: The Pfizer Interest Is Interesting
Dec 15Circling Back On Cardiff Oncology
Oct 12Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 26Cardiff Oncology: Current Slump Doesn't Look Right
Jun 14Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Apr 29How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?
Feb 28What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?
Jan 24CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$41m |
| Mar 31 2024 | n/a | n/a | -US$40m |
| Dec 31 2023 | US$2m | US$594k | -US$41m |
| Sep 30 2023 | n/a | n/a | -US$41m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$39m |
| Dec 31 2022 | US$2m | US$571k | -US$39m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$4m | US$533k | -US$28m |
| Sep 30 2021 | n/a | n/a | -US$25m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$24m |
| Dec 31 2020 | US$1m | US$445k | -US$23m |
| Sep 30 2020 | n/a | n/a | -US$20m |
| Jun 30 2020 | n/a | n/a | -US$20m |
| Mar 31 2020 | n/a | n/a | -US$17m |
| Dec 31 2019 | US$853k | US$399k | -US$17m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$16m |
| Mar 31 2019 | n/a | n/a | -US$19m |
| Dec 31 2018 | US$909k | US$387k | -US$19m |
| Sep 30 2018 | n/a | n/a | -US$18m |
| Jun 30 2018 | n/a | n/a | -US$18m |
| Mar 31 2018 | n/a | n/a | -US$20m |
| Dec 31 2017 | US$1m | US$374k | -US$25m |
報酬と市場: Mark's total compensation ($USD1.55M) is above average for companies of similar size in the US market ($USD655.65K).
報酬と収益: Mark's compensation has been consistent with company performance over the past year.
CEO（最高経営責任者
Mark Erlander (64 yo)
4.5yrs
在職期間
US$1,547,772
報酬
Dr. Mark Erlander, Ph D., is Chief Executive Officer of Cardiff Oncology, Inc. (formerly known as TrovaGene, Inc.) since May 2020 and was its Chief Scientific Officer March 4, 2013 to April 2020. Dr. Erlan...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 4.5yrs | US$1.55m | 0.053% $ 78.5k | |
| Chief Financial Officer | 3.3yrs | US$917.72k | 0.13% $ 192.3k | |
| Chief Medical Officer | 1.8yrs | US$1.26m | 0% $ 0 | |
| Chief Scientific Officer | 2.8yrs | US$4.17m | 0% $ 0 | |
| VP of Finance & Administration | 9.3yrs | データなし | データなし | |
| Senior Vice President of Finance | 1.8yrs | データなし | データなし | |
| Senior Vice President of Regulatory Affairs | 2.8yrs | データなし | データなし |
2.8yrs
平均在職期間
61.5yo
平均年齢
経験豊富な経営陣: CRDF's management team is considered experienced (2.8 years average tenure).
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 4.4yrs | US$1.55m | 0.053% $ 78.5k | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 4.6yrs | US$114.43k | 1.5% $ 2.2m | |
| Member of Scientific Advisory Board | 10.3yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 12yrs | US$35.85k | データなし | |
| Independent Chairman of the Board | 10.8yrs | US$154.43k | 0.067% $ 99.5k | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | 14.6yrs | データなし | データなし | |
| Independent Director | 4.6yrs | US$116.43k | 0.24% $ 364.7k | |
| Member of Scientific Advisory Board | 10.2yrs | データなし | データなし | |
| Independent Director | 3.4yrs | US$110.43k | 0.021% $ 32.0k | |
| Member of Scientific Advisory Board | 14.6yrs | データなし | データなし |
10.2yrs
平均在職期間
72yo
平均年齢
経験豊富なボード: CRDF's board of directors are seasoned and experienced ( 10.2 years average tenure).